[1]叶书磊.重组人促红素注射液联合左卡尼汀注射剂治疗终末期肾病肾性贫血的疗效及对患者心功能的影响[J].医学信息,2023,36(19):122-125.[doi:10.3969/j.issn.1006-1959.2023.19.026]
　YE Shu-lei.Effect of Recombinant Human Erythropoietin Injection Combined with Levocarnitine Injection in the Treatment of Renal Anemia in Patients with End-stage Renal Disease and its Effect on Cardiac Function[J].Journal of Medical Information,2023,36(19):122-125.[doi:10.3969/j.issn.1006-1959.2023.19.026]
点击复制

重组人促红素注射液联合左卡尼汀注射剂治疗终末期肾病肾性贫血的疗效及对患者心功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
122-125
栏目:
论著
出版日期:
2023-10-01

文章信息/Info

Title:
Effect of Recombinant Human Erythropoietin Injection Combined with Levocarnitine Injection in the Treatment of Renal Anemia in Patients with End-stage Renal Disease and its Effect on Cardiac Function
文章编号:
1006-1959（2023）19-0122-04
作者:
叶书磊
（广信区中医院肾内科，江西 上饶 334100）
Author(s):
YE Shu-lei
(Department of Nephrology,Guangxin District Hospital of Traditional Chinese Medicine,Shangrao 334100,Jiangxi,China)
关键词:
终末期肾脏病; 肾性贫血; 重组人促红素; 左卡尼汀; 心功能
Keywords:
End-stage renal disease; Renal anemia; Recombinant human erythropoietin; Levocarnitine; Cardiac function
分类号:
R544.1；R459.5
DOI:
10.3969/j.issn.1006-1959.2023.19.026
文献标志码:
A
摘要:
目的 研究重组人促红素注射液（rhEPO）联合左卡尼汀注射剂（LC）治疗终末期肾病（ESRD）肾性贫血的疗效及对患者心功能的影响。方法 以2019年6月-2022年6月广信区中医院收治的50例ESRD肾性贫血患者为研究对象，采用随机数字表法分为对照组（20例）和观察组（30例）。对照组给予rhEPO治疗，观察组应用rhEPO联合LC治疗，比较两组贫血治疗效果、血常规指标[红细胞（RBC）、血红蛋白（Hb）、红细胞比容（HCT）]、炎症指标[超敏C反应蛋白（hs-CRP）、白介素6（IL-6）]、心功能指标[血清脑钠肽（BNP）、左心室射血分数（LVEF）]及不良反应。结果 观察组贫血治疗总有效率高于对照组（P＜0.05）；两组治疗后RBC、Hb、HCT水平均高于治疗前，且观察组RBC、Hb、HCT高于对照组（P＜0.05）；两组治疗后hs-CRP、IL-6均低于治疗前，且观察组hs-CRP、IL-6低于对照组（P＜0.05）；两组治疗后BNP水平低于治疗前，LVEF高于治疗前，且观察组BNP水平低于对照组，LVEF高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 rhEPO联合LC治疗ESRD肾性贫血疗效突出，可有效纠正患者的血常规指标，下调体内炎症反应，同时改善心功能，且不增加不良反应，安全性良好。
Abstract:
Objective To study the therapeutic effect of recombinant human erythropoietin injection (rhEPO) combined with levocarnitine injection (LC) on renal anemia in patients with end-stage renal disease (ESRD) and its effect on cardiac function.Methods A total of 50 patients with ESRD renal anemia admitted to Guangxin District Hospital of Traditional Chinese Medicine from June 2019 to June 2022 were divided into control group (20 patients) and observation group (30 patients) by random number table method. The control group was treated with rhEPO, and the observation group was treated with rhEPO combined with LC. The therapeutic effect of anemia, blood routine indexes [red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT)], inflammatory indexes [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)], cardiac function indexes [serum brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF)] and adverse reactions were compared between the two groups.Results The total effective rate of anemia treatment in the observation group was higher than that in the control group (P<0.05). The levels of RBC, Hb and HCT in the two groups after treatment were higher than those before treatment, and the levels of RBC, Hb and HCT in the observation group were higher than those in the control group (P<0.05). After treatment, hs-CRP and IL-6 in the two groups were lower than those before treatment, and hs-CRP and IL-6 in the observation group were lower than those in the control group (P<0.05). After treatment, the BNP level of the two groups was lower than that before treatment, LVEF was higher than that before treatment, and the BNP level of the observation group was lower than that of the control group, LVEF was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion rhEPO combined with LC is effective in the treatment of ESRD renal anemia, which can effectively correct the blood routine indexes, down-regulate the inflammatory response in vivo, and improve the cardiac function without increasing adverse reactions, with good safety.

参考文献/References:

[1]邹贤顺,刘利生,汤锦美,等.重组人促红素联合蔗糖铁治疗维持性血液透析贫血患者的效果观察[J].实用临床医药杂志,2020,24(18):77-80.[2]张游,霍洁,邹欢,等.罗沙司他胶囊对比重组人促红素注射液治疗维持性血液透析肾性贫血的有效性及安全性[J].国际泌尿系统杂志,2022,42(3):394-397.[3]成水芹,周婷婷,张志宏,等.罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J].肾脏病与透析肾移植杂志,2022,31(1):9-14.[4]易尚亨,曾屏,陈俊斌.不同剂量重组人促红素对慢性肾脏病患者心脏功能和心电图的影响[J].中华生物医学工程杂志,2019,25(6):758-762.[5]方蕾,黄扬扬,伍学琪.罗沙司他与重组人促红素治疗维持性血液透析患者肾性贫血的效果[J].中国医药导报,2021,18(11):137-140.[6]张林海,柴星星,杨伏猛,等.单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响[J].中国医院用药评价与分析,2021,21(4):455-458.[7]郭友志.大剂量促红细胞生成素对血液透析患者肾性贫血的治疗效果及对血清铁蛋白叶酸水平的影响[J].山西医药杂志,2021,50(10):1668-1670.[8]中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J].中华医学杂志,2021,101(20):1463-1502.[9]白荷荷,聂晓静,王园姬.297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价[J].药物流行病学杂志,2018,27(6):392-395.[10]吴韵华,陆焕俊,王健生.蔗糖铁联合重组人促红素注射液治疗血液透析患者肾性贫血的疗效观察[J].贵州医药,2018,42(10):1188-1189.[11]李宏彬,梁军,马强.罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J].中国医药导报,2020,17(8):178-181.[12]何香芝.左卡尼汀联合促红细胞生成素治疗维持性血液透析肾性贫血临床效果研究[J].中国药物与临床,2020,20(21):3644-3646.[13]李晓燕,冯要菊.左卡尼汀联合促红细胞生成素纠正维持性血液透析患者肾性贫血的效果及对内皮素和左室重构的影响[J].药物评价研究,2017,40(4):521-524.[14]赵琳琳,田园,韩淑苗,等.左卡尼汀联合促红细胞生成素治疗血液透析肾性贫血的疗效[J].蚌埠医学院学报,2020,45(4):486-488,492.[15]李东峰,王冬梅.rhEPO联合左卡尼汀治疗对尿毒症患者血清内皮素及心功能的影响[J].中国医师杂志,2020,22(11):1744-1746.[16]欧阳山丹,林珍,李阿云.左卡尼汀对维持性血液透析患者肾性贫血的疗效及心脏结构和功能的影响[J].贵州医科大学学报,2019,44(5):601-605.[17]李静,李燕燕.左卡尼汀联合促红细胞生成素对维持性血液透析肾性贫血患者的临床疗效及心理状态的影响[J].国际精神病学杂志,2021,48(6):1076-1079,1105.[18]de Oliveira WV Jr,de Figueiredo RC,de Paula AS,et al.Study of association between interleukin-17 and interferon-gamma and recombinant human erythropoietin dose in patients undergoing peritoneal dialysis[J].Cytokine,2017,96:24-29.[19]赵娜,郭一丹,张春霞,等.重组人促红素联合左卡尼汀对老年血液透析患者肾性贫血治疗效果及氧化应激的影响[J].临床误诊误治,2021,34(4):33-38.[20]潘泽斌,郭喜.左卡尼汀对实施间歇性高通量血液透析治疗血液透析患者肾性贫血及微炎症状态的影响[J].中华保健医学杂志,2022,24(4):329-332.[21]张勇,侯娟.左卡尼汀联合促红细胞生成素治疗肾性贫血的疗效分析[J].临床肾脏病杂志,2018,18(3):176-179.

相似文献/References:

[1]宋瑞龙,卢 斐,黄艳莉.复方硫酸亚铁叶酸片联合促红细胞生成素治疗肾性贫血的疗效[J].医学信息,2019,32(24):145.[doi:10.3969/j.issn.1006-1959.2019.24.052]
　SONG Rui-long,LU Fei,HUANG Yan-li.Efficacy of Compound Ferrous Sulfate Folic Acid Tablets Combined with Erythropoietin in the Treatment of Renal Anemia[J].Journal of Medical Information,2019,32(19):145.[doi:10.3969/j.issn.1006-1959.2019.24.052]
[2]房 彩,孙蓓蓓,姚 博,等.KDQOL-SF量表评估社区血透中心维持性血液透析患者健康相关生活质量的意义[J].医学信息,2020,33(11):95.[doi:10.3969/j.issn.1006-1959.2020.11.027]
　FANG Cai,SUN Bei-bei,YAO Bo,et al.Significance of KDQOL-SF Scale to Evaluate the Health-related Quality of Life of Maintenance Hemodialysis Patients in Community Hemodialysis Centers[J].Journal of Medical Information,2020,33(19):95.[doi:10.3969/j.issn.1006-1959.2020.11.027]
[3]胡 岩.蔗糖铁联合重组人促红细胞生成素注射液治疗血液透析患者肾性贫血的疗效[J].医学信息,2021,34(14):157.[doi:10.3969/j.issn.1006-1959.2021.14.044]
　HU Yan.Effect of Sucrose Iron Combined with Recombinant Human Erythropoietin Injection on Renal Anemia in Hemodialysis Patients[J].Journal of Medical Information,2021,34(19):157.[doi:10.3969/j.issn.1006-1959.2021.14.044]
[4]周 浩,杨 林.终末期肾脏病合并不宁腿综合征治疗研究[J].医学信息,2022,35(13):74.[doi:10.3969/j.issn.1006-1959.2022.13.016]
　ZHOU Hao,YANG Lin.Research on the Treatment of End-stage Renal Disease with Restless Leg Syndrome[J].Journal of Medical Information,2022,35(19):74.[doi:10.3969/j.issn.1006-1959.2022.13.016]
[5]周 欣,冯诚怿,耿雯雯,等.基于CiteSpace的血液透析相关感染文献的可视化分析[J].医学信息,2023,36(15):51.[doi:10.3969/j.issn.1006-1959.2023.15.009]
　ZHOU Xin,FENG Cheng-yi,GENG Wen-wen,et al.Visual Analysis of Hemodialysis-related Infection Literature Based on CiteSpace[J].Journal of Medical Information,2023,36(19):51.[doi:10.3969/j.issn.1006-1959.2023.15.009]
[6]叶益舟,凌铭培,余 娟,等.罗沙司他与促红素在血液透析患者肾性贫血中的效果比较[J].医学信息,2024,37(16):52.[doi:10.3969/j.issn.1006-1959.2024.16.010]
　YE Yi-zhou,LING Ming-pei,YU Juan,et al.Comparison of the Effects of Rosalrestat Erythropoietin on Renal Anemia in Hemodialysis Patients[J].Journal of Medical Information,2024,37(19):52.[doi:10.3969/j.issn.1006-1959.2024.16.010]

更新日期/Last Update: 1900-01-01